CNSP: Bathi resik saben saham (EPS TTM) CNS Pharmaceuticals, Inc.

Simbol resmi perusahaan CNS Pharma (CNSP)

CNS Pharmaceuticals (CNSP) revenues are based on the market launch of the antineoplastic drug berubicine, although the high margins of its innovations provide colossal growth potential. The annual earnings per share trend confirms this balance, and the figure currently holds around -23.56. Price stability is supported by a cohesive management team that flawlessly coordinates international clinical trials.

CNSP (CNS Pharmaceuticals) riwayat Bathi resik saben saham sajrone patang kuartal pungkasan saka 04.07.2022 nganti 17.11.2026

CNSP (CNS Pharmaceuticals Corp): rincian analitis lan laporan miturut indikator

- kuotasi saiki lan rata-rata prakiraan nilai:
Pambiji fundamental:CNSP - CNS Pharmaceuticals Inc
Produk sing diprodhuksi CNS Pharma

Net income per share over 12 months distinguishes the actual value of the business from market expectations. By analyzing the rolling annual earnings per share, an investor sees the result of dividing the total annual profit by the total number of securities. This metric measures the actual efficiency of capital generation. For CNS Pharmaceuticals (CNSP), this figure reflects the cost of drug development with minimal expenditures on in-house management. Resource optimization via external consultants directly impacts the final yield of each share.